A Chinese medicine composition for treating ulcerative colitis, preparation method and use thereof
By developing a traditional Chinese medicine composition containing scutellaria baicalensis, somatosus ginseng, Panax notoginseng powder and other ingredients, the problems of unstable efficacy and major side effects in the treatment of ulcerative colitis were solved, and effective improvement of abdominal pain and diarrhea and intestinal mucosa were achieved. Healing and reducing the level of inflammatory factors.
Patent Information
- Application Number
- CN202310343217.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-03-31
AI Technical Summary
The existing treatment methods for ulcerative colitis have unstable efficacy, large side effects, high recurrence rates and lack of effective local medications, especially the type of traditional Chinese medicine enema, which is difficult to meet clinical needs.
A Chinese medicine composition has been developed, including Scutellaria baicalensis, Sophora glutinous rice, Panax notoginseng powder, fried white peony, red lily, sophora charcoal, green indica and pearl powder, which is prepared by water extraction and decoction, which has clear heat, dry dampness and cooling The effects of blood stopping bleeding, removing blood stasis and generating muscles are used to treat ulcerative colitis.
This traditional Chinese medicine composition significantly improved the symptoms of abdominal pain and diarrhea in clinical and experimentally, promoted intestinal mucosa healing, reduced the level of proinflammatory factors, improved the quality of life of patients, and in some aspects were better than positive medicines. The efficacy of salazine.
Smart Images

Figure CN116617296B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating ulcerative colitis, a preparation method and use thereof. Background Art
[0002] Ulcerative colitis (UC) is a chronic nonspecific inflammation of the colon and rectum with unclear etiology. The lesions are limited to the mucosa and submucosa of the large intestine. The lesions are mostly located in the sigmoid colon and rectum, and can also extend to the descending colon or even the entire colon. The main symptoms of ulcerative colitis include diarrhea, bloody and mucous stools, abdominal pain, tenesmus, etc. Extraintestinal manifestations in some patients are mainly arthritis, iridocyclitis, liver dysfunction and skin lesions. This disease is prone to occur in young people, seriously affecting the quality of life of patients. In addition, the course of the disease is prolonged and recurrent, and it is listed as one of the modern intractable diseases by the World Health Organization. The canceration rate of ulcerative colitis with a course of more than 10 years is 2%, 8% for more than 20 years, and 18% for more than 30 years. Therefore, controlling the inflammation of UC and strengthening the research on the protective mechanism of UC intestinal mucosa are not only meaningful for improving people's quality of life and work efficiency, but more importantly, it can further prevent it from developing into colorectal cancer, reduce the incidence of colorectal cancer, protect people's health, save health resources, and has important social significance.
[0003] The current treatment of UC is mainly based on 5-aminosalicylic acid (mesalazine), glucocorticoids, immunosuppressants and biological agents. In clinical use, oral preparations for overall treatment have toxic side effects such as unstable efficacy, easy relapse after discontinuation of medication, liver and kidney function damage and even bone marrow suppression, in addition to potential infection risks and high prices. Local use of mesalazine causes intestinal irritation and causes intolerance in some patients, resulting in poor patient compliance, making the current drug treatment of UC a difficult problem.
[0004] Traditional Chinese medicine believes that the lesion site of ulcerative colitis is in the large intestine, and the onset of the disease is closely related to the liver, spleen, and kidney. The onset of the disease is mostly due to spleen deficiency and poor function, endogenous dampness and turbidity, depression and heat; or exposure to external pathogens, damage to the spleen and stomach, and dampness and heat; or emotional disorders, damage to the liver and spleen, liver and spleen disharmony, qi stagnation and blood stasis, all of which can lead to dampness and heat accumulation in the large intestine, poor internal qi, stagnation of qi and blood, and pus, presenting symptoms such as diarrhea, mucus, pus and blood in the stool, abdominal pain and tenesmus. This disease has a long course, and the overall pathogenesis of this disease is the deficiency of the root and the excess of the superficial. Generally, the evil is the main in the early stage, mostly dampness and heat accumulation, qi and blood stagnation in the large intestine, and it does not heal for a long time during the transformation of symptoms, so it is transformed into spleen qi deficiency, spleen yang deficiency, spleen and kidney yang deficiency, manifested as mixed cold and heat.
[0005] Chinese medicine treatment based on syndrome differentiation and treatment, combined with oral and topical application, has significant efficacy in the treatment of UC, low recurrence rate, and few side effects. It has obvious advantages in inducing remission, synergizing with Western medicine to increase efficacy and reduce toxicity, improving patients' quality of life and preventing recurrence, and has become a hot topic of current research. At present, the main Chinese patent medicines for the treatment of UC are Xianglian Pills, Guben Yichang Tablets, Compound Kushen Enteric-coated Capsules, Hudi Enteric-coated Capsules and Xilei Powder. Most of the drugs are still oral dosage forms. The current domestic and international UC guidelines emphasize the combination of oral and topical medications to better improve the clinical efficacy of UC, but the current market lacks local dosage forms such as Chinese medicine enema solutions with proven efficacy. Therefore, it is very necessary to develop innovative Chinese medicines with different dosage forms for the treatment of ulcerative colitis based on clinical efficacy. Summary of the invention
[0006] Therefore, the technical problem to be solved by the present invention is to provide a Chinese medicine composition for treating ulcerative colitis, a preparation method and use thereof.
[0007] To this end, the present invention provides the following technical solutions:
[0008] A Chinese medicine composition, comprising the following raw materials in parts by weight:
[0009] 5-15 parts by weight of Scutellaria baicalensis charcoal, 5-15 parts by weight of Sophora flavescens, 1-3 parts by weight of Panax notoginseng powder, 5-15 parts by weight of stir-fried white peony root, 3-12 parts by weight of red ochre, 3-12 parts by weight of Sophora japonica charcoal, 1-3 parts by weight of Indigo naturalis, and 0.3-3 parts by weight of pearl powder.
[0010] Optionally, the raw materials include the following parts by weight:
[0011] 10-15 parts by weight of Scutellaria baicalensis charcoal, 10-15 parts by weight of Sophora flavescens, 1-3 parts by weight of Panax notoginseng powder, 10-15 parts by weight of stir-fried white peony root, 8-12 parts by weight of red ochre, 8-12 parts by weight of Sophora japonica charcoal, 2-3 parts by weight of Indigo naturalis, and 0.6-2 parts by weight of pearl powder.
[0012] Optionally, the raw materials include the following parts by weight:
[0013] 15 parts by weight of Scutellaria baicalensis charcoal, 12 parts by weight of Sophora flavescens, 3 parts by weight of Panax notoginseng powder, 12 parts by weight of stir-fried white peony root, 12 parts by weight of red ochre, 12 parts by weight of Sophora japonica charcoal, 3 parts by weight of Indigo naturalis, and 0.6 parts by weight of pearl powder.
[0014] A method for preparing the Chinese medicine composition comprises:
[0015] Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, extract them with water, and then add Panax notoginseng powder and pearl powder to the obtained water extract.
[0016] Optional, including:
[0017] Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, add 4-6 times the weight of water to the obtained mixture, soak for 0.5-1 hour, then boil the obtained soaking liquid to 95-100° C., cool it to 90-95° C. and boil it for 0.5-1 hour, filter it to obtain the first extract and the residue;
[0018] Add 2-4 times the weight of water to the medicinal residue, then boil to 95-100° C., then cool to 90-95° C. and boil for 0.5-1 hour, and filter to obtain a second extract;
[0019] Mix the first extract and the second extract, and then add Panax notoginseng powder and pearl powder.
[0020] A Chinese medicine preparation comprises the Chinese medicine composition prepared by the Chinese medicine composition or the preparation method of the Chinese medicine composition as an active ingredient.
[0021] Optionally, it also includes pharmaceutically acceptable excipients;
[0022] Optionally, the Chinese medicine preparation includes a liquid preparation or a solid preparation;
[0023] Optionally, the dosage form of the traditional Chinese medicine preparation includes enema, injection, tablet, capsule, powder, granule or paste.
[0024] The Chinese medicine composition, the Chinese medicine composition prepared by the method for preparing the Chinese medicine composition or the Chinese medicine preparation have the following uses:
[0025] (1) Use in the preparation of drugs for relieving, assisting in the treatment or treating ulcerative colitis;
[0026] (2) Use in the preparation of drugs for relieving, assisting in the treatment or treating abdominal pain and / or diarrhea;
[0027] (2) Use in the preparation of medicines having the effects of clearing away heat and dampness, cooling blood and stopping bleeding and / or removing blood stasis and promoting tissue regeneration.
[0028] Optionally, the ulcerative colitis is caused by damp-heat and blood stasis blocking the qi mechanism and / or intestinal corruption; and / or the ulcerative colitis is caused by intestinal mucosal damage, increased levels of proinflammatory factor IL-1β, increased levels of proinflammatory factor TNF-α, increased levels of proinflammatory factor MPO and / or decreased levels of anti-inflammatory factor TGF-β.
[0029] In the above Chinese medicine composition:
[0030] Scutellaria baicalensis charcoal has the effects of clearing away heat and dampness, purging fire and detoxifying, stopping bleeding and stabilizing pregnancy. Roasting the charcoal enhances the hemostatic effect.
[0031] Sophora flavescens has the effects of clearing away heat and dampness, killing insects and promoting diuresis.
[0032] Panax notoginseng powder has the effects of removing blood stasis and stopping bleeding, promoting blood circulation and relieving pain.
[0033] Fried white peony root has the effects of nourishing blood and regulating menstruation, astringing yin and stopping sweating, softening the liver and relieving pain, and calming liver yang.
[0034] Red ochre can astringe the intestines, stop diarrhea, and stop bleeding. When used externally, it can astringe and promote tissue regeneration, and heal ulcers.
[0035] Sophora japonica flowers, cool blood and stop bleeding.
[0036] Indigo, clears away heat, detoxifies and cools the blood.
[0037] Pearl powder has astringent and muscle-building effects.
[0038] The technical solution of the present invention has the following advantages:
[0039] 1. A Chinese medicine composition provided by the present invention comprises the following raw materials in weight: 5-15 weight parts of scutellaria baicalensis charcoal, 5-15 weight parts of sophora flavescens, 1-3 weight parts of Panax notoginseng powder, 5-15 weight parts of stir-fried white peony root, 3-12 weight parts of red ochre, 3-12 weight parts of sophora japonica charcoal, 1-3 weight parts of indigo, and 0.3-3 weight parts of pearl powder; the inventor of the present invention has been engaged in clinical and basic research on the treatment of ulcerative colitis with traditional Chinese medicine for a long time. Combining the endoscopic manifestations of the disease, it is believed that the key pathogenesis lies in damp-heat stasis blocking the qi mechanism and intestinal rot and collateral failure, and has created the Chinese medicine composition with the effects of clearing heat and drying dampness, cooling blood and stopping bleeding, and removing blood stasis and promoting tissue regeneration of the present invention. The Chinese medicine composition uses scutellaria baicalensis charcoal and sophora flavescens as the main ingredients. Scutellaria baicalensis is bitter and cold in nature, clears heat and dries dampness, and is the main medicine for treating damp-heat diarrhea. The charcoal is used to enhance the power of cooling blood and stopping bleeding; sophora flavescens is bitter and cold in nature, clears heat and dries dampness, and the two are the main ingredients, clearing heat and drying dampness and stopping diarrhea. Panax notoginseng powder is sweet and warm, can dissipate blood stasis and stop bleeding, promote blood circulation and stop pain; white peony root is sour, sweet and slightly cold, nourishes blood, softens the liver and stops pain, and is an important medicine for stopping dysentery. They are all ministerial drugs, dissipating blood stasis, stopping bleeding and stopping pain. Indigo is salty and cold, which enhances the power of the monarch drug to clear heat and cool blood; Sophora japonica charcoal is bitter and slightly cold, which enhances cooling blood and stopping bleeding; red ochre is sweet, sour, astringent and warm, astringes the intestines and stops diarrhea, and regenerates sores and promotes tissue regeneration. Pearl powder is sweet, salty and cold, astringent and regenerates tissue. The four drugs are all adjuvant drugs, cooling blood and stopping bleeding, stopping diarrhea and promoting tissue regeneration. The above-mentioned Chinese medicine composition has the functions and indications of clearing heat and dampness, cooling blood and stopping bleeding, dissipating blood stasis and promoting tissue regeneration. It is used for enema treatment of ulcerative colitis.
[0040] According to preliminary statistics by the inventors of the present invention, the Chinese medicine composition of the present invention can effectively improve abdominal pain, diarrhea and related symptoms of patients in outpatients with ulcerative colitis, and can also effectively promote the healing of the intestinal mucosa of patients. Furthermore, it was found in the experiment that compared with UC model mice, the Chinese medicine composition of the present invention can effectively reduce the disease activity score, repair intestinal mucosal damage, reduce the levels of pro-inflammatory factors IL-1β, TNF-α, and MPO, and increase the level of anti-inflammatory factor TGF-β. Its therapeutic effect is better than that of the positive drug mesalazine in some aspects. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0042] Figure 1 is the weight percentage of each group of mice in the experimental examples of the present invention;
[0043] Figure 2 is the fecal trait score of each group of mice in the experimental example of the present invention;
[0044] Figure 3 is the fecal occult blood score of each group of mice in the experimental example of the present invention;
[0045] Figure 4 is the DAI score of each group of mice in the experimental example of the present invention;
[0046] Figure 5 It is the HE staining result of colon tissue of each group of mice in the experimental example of the present invention;
[0047] Figure 6 It is the result of measuring the pro-inflammatory factor IL-1β in the colon tissue of each group of mice in the experimental example of the present invention;
[0048] Figure 7 It is the result of measuring the pro-inflammatory factor and anti-inflammatory factor TGF-β in the colon tissue of each group of mice in the experimental example of the present invention;
[0049] Figure 8 It is the result of measuring the anti-inflammatory factor TNF-α in the colon tissue of each group of mice in the experimental example of the present invention;
[0050] Fig. 9 These are the results of measuring the pro-inflammatory factor MPO in the colon tissue of each group of mice in the experimental examples of the present invention. DETAILED DESCRIPTION
[0051] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0052] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.
[0053] Example
[0054] This embodiment provides the Chinese medicine composition of Embodiments 1-5, and its formula is as shown in the following table.
[0055] Table 1. Formula of Chinese medicine composition
[0056]
[0057] The preparation method of the Chinese medicine composition of Example 1 is as follows:
[0058] Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, add water 5 times the weight of the mixture to the obtained mixture, soak for 0.8 hours, then boil the soaking liquid to 100° C., cool it to 95° C. and boil it for 0.8 hours, filter to obtain the first extract and the residue;
[0059] Add 3 times the weight of water to the residue, then boil to 100°C, then cool to 95°C and boil for 0.8 hours, and filter to obtain a second extract;
[0060] Mix the first extract and the second extract, then add Panax notoginseng powder and pearl powder and mix well.
[0061] The preparation method of the Chinese medicine composition of Example 2 is as follows:
[0062] Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, add water 4 times the weight of the mixture to the obtained mixture, soak for 0.5 hours, then boil the soaking liquid to 95°C, cool it to 90°C and boil it for 0.5 hours, filter to obtain the first extract and the residue;
[0063] Add 2 times the weight of water to the residue, boil to 95°C, cool to 90°C, boil for 0.5 hours, and filter to obtain a second extract;
[0064] Mix the first extract and the second extract, then add Panax notoginseng powder and pearl powder and mix well.
[0065] The preparation method of the Chinese medicine composition of Example 3 is as follows:
[0066] Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, add 6 times the weight of water to the obtained mixture, soak for 1 hour, then boil the soaking liquid to 98°C, cool it to 93°C and boil for 1 hour, filter to obtain the first extract and the residue;
[0067] Add 4 times the weight of water to the residue, boil to 98°C, cool to 93°C and boil for 1 hour, filter to obtain a second extract;
[0068] Mix the first extract and the second extract, then add Panax notoginseng powder and pearl powder and mix well.
[0069] The preparation methods of the Chinese medicine compositions of Examples 4-5 and Comparative Examples 1-2 are the same as those of Example 1. The preparation method of Comparative Example 1 lacks the steps of weighing and adding the raw materials of Scutellaria baicalensis charcoal, Panax notoginseng powder, Sophora japonica charcoal, and pearl powder according to the formula. The preparation method of Comparative Example 2 lacks the steps of weighing and adding the raw materials of Sophora flavescens, stir-fried white peony root, red ochre, and Indigo naturalis according to the formula.
[0070] Experimental Example Observation of the efficacy of the Chinese medicine composition of the present invention on UC model animals
[0071] 1 Materials and methods
[0072] 1.1. Experimental animals
[0073] 60 SPF-grade C57BL / 6 male mice, weighing 20±2g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd., license number: SCXK (Beijing) 2019-0010. They were kept in the experimental animal room of Beijing University of Chinese Medicine with a 12h light / dark cycle, temperature of 23-27℃, and humidity of 40%-60%; they were fed with free food and water.
[0074] 1.2. Experimental drugs and dosage
[0075] Traditional Chinese medicine: the traditional Chinese medicine compositions of Examples 1-5 and Comparative Examples 1-2.
[0076] Positive drugs:
[0077] Mesalazine enema solution (Salford, approval number H20150127).
[0078] 1.3. Main reagents and instruments
[0079] Dextran sulfate sodium (DSS, MW36-50KDa; MP Biomedical, Burlingame, CA, USA); fecal occult blood test strips (Zhuhai Beso Biotechnology Co., Ltd.); hematoxylin and eosin stains, Beijing Gaojia Biotechnology Co., Ltd.; pathological paraffin embedding machine, Shenyang Longshou Electronic Instrument Co., Ltd., model LS-100; paraffin sectioner, Beijing Hongtai Jiaye Technology Development Co., Ltd., model Finesse 325; microscope, Olympus Corporation, model BX60; ELISA kits for determining IL-1β, TGF-β, TNF-α, and MPO levels in colon tissue were purchased from Shanghai ELISA Biotechnology Co., Ltd.
[0080] 1.4. Animal modeling, grouping and drug administration
[0081] The mice were randomly divided into a blank group, a model group, examples 1-5 and comparative examples 1-2, and a positive drug control group using EXCEL random numbers, with 6 mice in each group, and adaptively fed for 7 days. Except for the blank group, the remaining mice were allowed to freely drink 3% DSS to establish a UC model for 7 consecutive days.
[0082] During the modeling period, the blank group and the model group were given enema with distilled water at a dose of 0.1 ml / 10 g, and the other groups were given enema with the corresponding drugs at a dose of 0.1 ml / 10 g, once a day for 7 consecutive days.
[0083] 1.5.Indicator detection and methods
[0084] 1.5.1. General observations
[0085] During the experiment, the general behavioral changes of mice, such as mental state, free activity, hair condition, etc., were observed and recorded. The mice were weighed daily, stool characteristics were observed, fecal occult blood was detected, and the disease activity index (DAI) was calculated (see Table 2).
[0086] Table 2. DAI scoring criteria
[0087]
[0088] Note: DAI = (weight score + stool characteristics score + fecal occult blood score) / 3
[0089] 1.5.2. Observation of pathological changes in mouse colon tissue by HE staining
[0090] Pentobarbital was injected intraperitoneally for anesthesia, and then the complete colon was dissected for pathological histological examination. The tissue samples fixed with 4% paraformaldehyde were taken out, embedded in paraffin, and sliced with a thickness of 5 μm according to the conventional method. HE staining was performed, and the colon gland structure, goblet cells, crypt structure, inflammatory infiltration, etc. were observed under a microscope, and the degree of colon lesions in each group was compared.
[0091] 1.5.3. Determination of inflammatory factors in colon tissue
[0092] After the colon tissue was ground, it was centrifuged in a low-temperature centrifuge at 4°C for 15 minutes (3000 rpm), the supernatant was separated, and stored in a refrigerator at -20°C. The levels of IL-1β, TGF-β, TNF-α, and MPO in colon tissue were determined by ELISA.
[0093] 2. Statistics
[0094] SPSS 26.0 software was used for data analysis. Normally distributed quantitative data were statistically described by mean ± standard deviation, and one-way analysis of variance was used to compare the mean values between groups; non-normally distributed quantitative data and technical data were statistically described by median (interquartile range), and non-parametric rank sum test was used to compare the differences between groups. P < 0.05 was considered to be statistically different, and P < 0.01 was considered to be statistically significant.
[0095] 3 Results
[0096] 3.1 General condition and DAI scores of mice in each group
[0097] like Figure 1 As shown, the weight of the mice in the blank group did not decrease, and it increased steadily. The model group lost weight significantly; the weight loss trend of the mice in the embodiment groups and the mesalazine group during the experiment was significantly reduced compared with the model group, and the weight loss trend of the control groups 1 and 2 during the experiment was not significantly reduced compared with the model group. After the modeling began, the stool characteristics of the blank group were normal, and the stool characteristics of the other groups changed, occult blood in the stool (+) or blood in the stool was gradually aggravated, and the DAI score of each group gradually increased. The growth trend of the embodiment groups and the mesalazine group was slow ( Figure 2-4 ).
[0098] 3.2 Changes in colon length of mice in each group
[0099] Compared with the blank group, the colon length of mice in the model group was significantly shortened (P<0.01); compared with the model group, after intervention with Examples 1-5 and mesalazine, the colon length of mice was significantly improved (P<0.05 or p<0.01 or p<0.001), while there was no significant improvement after intervention with Comparative Example 1-2.
[0100] Table 3 Colon length of mice in each group (cm)
[0101]
[0102] Note: *p<0.05 compared with the model group, **p<0.01 compared with the model group, ***p<0.001 compared with the model group, ns: no statistical significance compared with the model group.
[0103] 3.3 Pathological changes of colon tissue in each group of mice
[0104] Observe the pathological sections under the microscope. Figure 5 As shown, the blank group had normal colon tissue structure, neat texture, and no lesions in the intestinal mucosa. In the model group, changes in the submucosal crypt structure, reduced mucus secretion, reduced goblet cells, and inflammatory cell infiltration were observed. Compared with the model group, after the intervention of each embodiment, comparative example, and mesalazine, the crypt structure of the colon tissue was restored, mucus secretion and the number of goblet cells increased, and the number of inflammatory cells decreased. Relative to Examples 1-5, Comparative Examples 1-2 still showed changes in the submucosal crypt structure, reduced mucus secretion, reduced goblet cells, and inflammatory cell infiltration.
[0105] 3.4 Changes in the expression levels of inflammatory factors in colon tissue of mice in each group
[0106] The ELISA method was used to detect the changes in the expression levels of the pro-inflammatory factor IL-1β, the anti-inflammatory factor TGF-β, the pro-inflammatory factor TNF-α, and the pro-inflammatory factor MPO in the colon tissues of each group of mice. Figure 6 , Figure 7 , Figure 8 , Fig. 9 As shown, compared with the blank group, the levels of pro-inflammatory factors IL-1β, TNF-α, and MPO in the model group mice were significantly increased (P<0.001), and the level of anti-inflammatory factor TGF-β was reduced (P<0.001); compared with the model group, after intervention with each embodiment and mesalazine, the level of pro-inflammatory factors in the colon tissue of mice was significantly reduced, and the level of anti-inflammatory factors was significantly increased, while after intervention with the comparative examples 1 and 2, the level of pro-inflammatory factors in the colon tissue of mice was not significantly reduced, and the level of anti-inflammatory factors was not significantly increased. Note: *p<0.05 compared with the model group, **p<0.01 compared with the model group, ***p<0.001 compared with the model group, ns: compared with the model group, there is no statistical significance.
[0107] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A Chinese medicine composition for treating ulcerative colitis, characterized in that: It is composed of the following raw materials in parts by weight: 5-15 parts by weight of Scutellaria baicalensis charcoal, 5-15 parts by weight of Sophora flavescens, 1-3 parts by weight of Panax notoginseng powder, 5-15 parts by weight of stir-fried white peony root, 3-12 parts by weight of red ochre, 3-12 parts by weight of Sophora japonica charcoal, 1-3 parts by weight of Indigo naturalis, and 0.3-3 parts by weight of pearl powder.
2. The Chinese medicine composition for treating ulcerative colitis according to claim 1, characterized in that: It is composed of the following raw materials in parts by weight: 10-15 parts by weight of Scutellaria baicalensis charcoal, 10-15 parts by weight of Sophora flavescens, 1-3 parts by weight of Panax notoginseng powder, 10-15 parts by weight of stir-fried white peony root, 8-12 parts by weight of red ochre, 8-12 parts by weight of Sophora japonica charcoal, 2-3 parts by weight of Indigo naturalis, and 0.6-2 parts by weight of pearl powder.
3. The Chinese medicine composition for treating ulcerative colitis according to claim 1 or 2, characterized in that: It is composed of the following raw materials in parts by weight: 15 parts by weight of Scutellaria baicalensis charcoal, 12 parts by weight of Sophora flavescens, 3 parts by weight of Panax notoginseng powder, 12 parts by weight of stir-fried white peony root, 12 parts by weight of red ochre, 12 parts by weight of Sophora japonica charcoal, 3 parts by weight of Indigo naturalis, and 0.6 parts by weight of pearl powder.
4. A method for preparing a Chinese medicine composition for treating ulcerative colitis according to any one of claims 1 to 3, characterized in that: include: Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, extract them with water, and then add Panax notoginseng powder and pearl powder to the obtained water extract.
5. The method for preparing the Chinese medicine composition for treating ulcerative colitis according to claim 4, characterized in that: include: Weigh the raw materials according to the formula, mix the other raw materials except Panax notoginseng powder and pearl powder, add 4-6 times the weight of water to the obtained mixture, soak for 0.5-1 hour, then boil the obtained soaking liquid to 95-100° C., cool it to 90-95° C. and boil it for 0.5-1 hour, filter it to obtain the first extract and the residue; Add 2-4 times the weight of water to the medicinal residue, then boil to 95-100° C., then cool to 90-95° C. and boil for 0.5-1 hour, and filter to obtain a second extract; Mix the first extract and the second extract, and then add Panax notoginseng powder and pearl powder.
6. A Chinese medicine preparation, characterized in that: The Chinese medicine composition for treating ulcerative colitis according to any one of claims 1 to 3 or the Chinese medicine composition for treating ulcerative colitis according to claim 4 or 5 is the active ingredient.
7. The Chinese medicine preparation according to claim 6, characterized in that: Pharmaceutically acceptable excipients are also included.
8. The Chinese medicine preparation according to claim 7, characterized in that: The traditional Chinese medicine preparation is in the form of a liquid preparation or a solid preparation.
9. The Chinese medicine preparation according to claim 8, characterized in that: The dosage form of the traditional Chinese medicine preparation is enema, injection, tablet, capsule, powder, granule or paste.
10. Use of the Chinese medicine composition for treating ulcerative colitis according to any one of claims 1 to 3, the Chinese medicine composition prepared by the preparation method of the Chinese medicine composition for treating ulcerative colitis according to claim 4 or 5, or the Chinese medicine preparation according to any one of claims 6 to 9 in the preparation of the following drugs: (1) Use in the preparation of drugs for relieving, assisting in the treatment or treating ulcerative colitis; (2) Use in the preparation of drugs for relieving, assisting in the treatment or treating abdominal pain and / or diarrhea.
